Meeting Report

Staying Abreast of New Biomarkers in Hematology/Oncology

Presented by Andrew Guinigundo,(1) MSN, RN, CNP, ANP-BC, FAPO, and Grace Baek,(2) PharmD, BCOP

There has been an increasing number of approvals for targeted therapies in oncology in the past decade, changing the treatment paradigm for many solid tumors and hematologic malignancies. At JADPRO Live 2023, presenters provided an in-de...

2022–2023 Drug Updates in Solid Tumors

Presented by Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

At JADPRO Live 2023 in Orlando, Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, briefed advanced practitioners on key US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Holle described indications, mechanisms of actio...

2022–2023 Drug Updates in Hematologic Malignancies

Presented by Rebecca L. Rezac, PharmD, BCOP

At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring an...

2022–2023 Drug Updates: Investigational Therapeutics in the Pipeline

Presented by Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

During JADPRO Live 2023, Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Cuellar highlighted new drug classes, novel mechanisms of action, and safety profiles...

Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer

Presented by Stephanie L. Graff,(1,2) MD, FACP, FASCO, Christine McGinn,(1) MSN, APRN, ACNP-BC, and Jeanine R. Showalter,(3) MSN, APRN, FNP-BC, AOCNP®

At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status,...

Advancing Precision-Targeted Treatment for Patients With Metastatic Non–Small Cell Lung Cancer

Presented by Tajuana Bradley,(1) MSN, APRN-BC, and Beth Sandy,(2) MSN, CRNP, FAPO

At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecu...

Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice

Presented by Mary B. Morgan,(1) MSN, ANP-BC, AOCN®, and Tammy Triglianos,(2) DNP, ANP-BC, AOCNP®

At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider...

Improving Prostate Cancer Patient Care in the Clinical Setting

Presented by Jessica Deinert, MSN, APRN, FNP-C, AOCNP®, and Leah K. Shaw, MSN, APRN, AGPCNP-BC

At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies ba...

Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs

Presented by Beth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD

At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, tre...

Racial Disparities, Advanced Ovarian Cancer, and HER2 Expression: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner

Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC

Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies. He also describes the phase III D...

Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner

Lisa Kottschade, APRN, MSN, CNP, FAPO

Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the us...

Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner

Oxana Megherea, PharmD, BCOP

Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolle...

Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology

Presented by Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO, Sandra E. Kurtin,(2) PhD, ANP-C, AOCN®, FAPO, and Rasheda Persinger,(3) MSN, AGNP-C, AOCNP®

In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biom...

2021–2022 Drug Updates in Solid Tumors

Presented by Kirollos Hanna, PharmD, BCPS, BCOP

During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanis...

2021–2022 Drug Updates in Hematologic Malignancies

Presented by Jenni Tobin, PharmD

During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr....

2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline

Presented by Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechani...

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC

Presented by Narjust Florez (Duma), MD, and Stephanie McDonald, NP

The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from ...

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer

Presented by Marcie Beasley, FNP-C, AOCNP®, and Brooke Daniel, MD

HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters di...

Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Presented by Cesar Rodriguez, MD, and Donna Catamero, ANP-BC, OCN®, CCRC

Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations th...

What Does Dobbs v. Jackson Mean for Oncology Patients and Providers? Current Considerations for Pregnancy and Fertility in the Oncology Setting

Presented by Brianna Hoffner,(1) MSN, ANP-BC, AOCNP®, FAPO, Leslie C. Appiah,(2) MD, Alexis C. Geppner,(3) MLS, CTTS, MPAS, PA-C, Laxmi A. Kondapalli,(4) MD, MSCE, and Govind Persad,(5) JD, PhD

The incidence of cancers such as colorectal cancer, head and neck cancer, and melanoma has increased in younger patients. The number of cancer survivors is also increasing in the US. Pairing these facts together, there are many people wi...

Uncovering and Addressing Implicit Bias in Oncology

Presented by Rose DiMarco,(1) PharmD, BCPS, BCOP, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, and Caressa Valdueza,(3) MSN, AGNP-C

Implicit bias affects patient care every day, and not just in oncology. It impacts decision-making in already vulnerable populations such as the historically marginalized racial and ethnic groups, the LGBTQI+ population, patients with di...

Best Practices in the Management of Infectious Complications for Patients With Cancer: Management of Febrile Neutropenia

Presented by Kyle C. Molina, PharmD, BCIDP, AAVHIP

Managing infection in patients with neutropenia is a difficult challenge, as fever is often the only clinical symptom. At JADPRO Live 2022, Kyle C. Molina, PharmD, BCIDP, AAVHIP, of the University of Colorado Hospital, discussed the epid...

Medical Aid in Dying: Ethical and Practical Issues

Presented by Jonathan Treem, MD

At JADPRO Live 2022, Jonathan Treem, MD, of the University of Colorado Palliative Care, explained medical aid in dying in order to prepare advanced practitioners to feel confident to counsel a patient who inquiries about aid in dying. He...

Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment

Presented by Keri Halsema, NP, and Brandon McMahon, MD

The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to pro...

Managing the Patient With Multiple Primary Tumors

Presented by Holly Chitwood, DNP, APRN, FNP, AGACNP, and Tamara Carey, MSN, APRN, FNP

Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types withou...

Clinical Posters From JADPRO Live 2022

Thirty-six clinical posters focused on the role of the advanced practitioner were presented at JADPRO Live this past October 20 to 23, 2022, in Aurora, Colorado. View the poster listing here, and access the abstracts, posters, and audio ...

Genitourinary Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Emily Lemke, DNP, AGPCNP-BC, AOCNP®

Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of the Medical College of Wisconsin Cancer Center, comments on MET and CTLA-4 inhibitors for clear cell renal cell carcinoma, maintenance targeted therapy for patients with metastatic urothelial carci...

Gynecologic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital/Brown University, interprets data presented at the 2022 ASCO Annual Meeting on rucaparib maintenance in advanced ovarian cancer, single-agent trabectedin in BRCA-positive ova...

Melanoma: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Suzanne McGettigan, MSN, CRNP, AOCN®

Suzanne McGettigan, MSN, CRNP, AOCN®, of Abramson Cancer Center of the Hospital of the University of Pennsylvania, reviews data on adjuvant therapy in stage IIB or IIC melanoma and omitting lymph node dissection and adjuvant therapy in p...

Head and Neck Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Heidi Mason, DNP, ACNP-BC

Heidi Mason, DNP, ACNP-BC, of the University of Michigan School of Nursing, considers research on avoiding concurrent chemotherapy in patients with nasopharyngeal carcinoma being treated with radiotherapy and a clinical trial on concurre...

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

P. Andrew Allred, MS, PA-C, Amy Pierre, MSN, ANP-BC, Meredith Beaton, MSN, RN, Pamela Lee, NP, MSN, and Amber Koehler, PA-C

P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, considers data on managing newly diagnosed MM and CAR T-cell therapy in MM. Amy Pierre, MSN, ANP-BC, of MSKCC and Flatiron Health, reviews findings on telemedicine inequiti...

The AP Role in Clinical Research: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth Koselke, PharmD, BCOP and Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP®

Elizabeth Koselke, PharmD, BCOP, of The US Oncology Network, describes a clinical pharmacist intervention to screen patients and improve clinical trial enrollment. Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP®, of the University of Haw...

Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Jacquelyn Lauria, RN, APN, AOCNP® and Rose DiMarco, PharmD, BCPS, BCOP

Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast can...

Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung ...

Gastrointestinal Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN® and Kristen O’Hagan, MSN, ANP-BC, AOCNP®

Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on RAS wild-type metastatic colorectal cancer, locally advanced mismatch repair–deficient rectal cancer, circulating tumor DNA tests, pancreatic neuroe...

Multidisciplinary Management of Resectable Early-Stage Non-Small Cell Lung Cancer

Jennifer Jacky,(1) MSN, ARNP, AOCNP®, Kristin DeGroot,(2) PA-C, and Rebecca Denney,(2) PA-C

During JADPRO Live Virtual 2021, three advanced practitioners—in surgery, radiation oncology, and medical oncology—discussed their collaboration in the management of resectable early-stage non–small cell lung cancer. The presenters discu...

Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective

R. Donald Harvey,(1) PharmD, BCOP, FCCP, FHOPA, Aaron Begue,(2) MS, RN, NP-C, Caleb Raine,(1) PA-C, and Robin Yabroff,(3) PhD, MBA

At the opening session of JADPRO Live Virtual 2021, panelists shared creative responses to the COVID-19 pandemic and considered strategies to effectively respond to crises that may impact cancer patients and practices in the future.

Pull Up a Seat: Engaging Patients as Empowered Partners in Health Equity Transformation

by Maimah Karmo,(1) and Amy Pierre,(2),(3) MSN, ANP-BC

At the JADPRO Live Virtual 2021 keynote interview, Maimah Karmo, CEO and Founder of the Tigerlily Foundation, spoke with Amy Pierre, MSN, ANP-BC, on her breast cancer experience and drive to establish an organization that educates, advoc...

Identifying the Leader in You

Elisabeth King,(1) FNP-C, and Sara Toth,(2) FNP-C

The leadership journey is often a long and winding road, with speed bumps and unexpected turns. During this session of JADPRO Live Virtual, presenters discussed the leadership qualities that they have found integral, including emotional ...

Thriving, Not Just Surviving: Recognizing Burnout and Simple Tips to Start Feeling Better

Margaret Leddy, PA-C, MMSc

Burnout has been prevalent since before COVID-19 and continues to affect a large portion of the health-care workforce. At JADPRO Live Virtual 2021, Margaret Leddy, PA-C, MMSc, defined burnout in the setting of the oncology/hematology adv...

A Call to Action: The Role of the Oncology AP in Equitable Cancer Care

Brianna Hoffner,(1) MSN, ANP-BC, AOCNP®, Josh Epworth,(2) ARNP, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, FAAN, and Soumya J. Niranjan,(4) BPharm, MS, PhD

The COVID-19 pandemic has only further brought to light how racism, bias, and lack of equity can result in social injustice, morbidity, and mortality. A panel of four advanced practitioners convened at JADPRO Live Virtual 2021 to examine...

The Advanced Practice Role in Clinical Trials: Past, Present, and Future

Colleen Lewis, MSN, ANP-BC, AOCNP®

At JADPRO Live Virtual 2021, Colleen Lewis, MSN, ANP-BC, AOCNP®, discussed the trajectory of the advanced practitioner role in clinical research, including the historical experience, potential barriers to practice, and future possibiliti...

Race, Social Determinants of Health, and Cancer: How Can APs Address and Improve Patient Outcomes?

Rose DiMarco,(1) PharmD, BCPS, BCOP, and Lisania Milli,(2) MSN, RN, WHNP-BC

The data show that racial and ethnic minority groups throughout the United States experience higher rates of illness and death across a wide range of health conditions when compared to their White counterparts. This session at JADPRO Liv...

Multidisciplinary Tumor Boards and Guiding Patient Care: The AP Role

Joan Okasako,(1) MSN, FNP-BC, RN, AOCNP®, and Carolyn Bernstein,(2) MSN, FNP-BC, RN

The history of multidisciplinary tumor boards extends to more than 50 years ago. At JADPRO Live Virtual 2021, presenters discussed the evidence-based impact of tumor boards on patient outcomes and patient-centered care, reviewed benefits...

Clinically Relevant Drug Interactions in the Cancer Setting

David DeRemer, PharmD, BCOP, FCCP, FHOPA

Along with the fast pace of oncology drug approvals is the heightened opportunity for drug-drug, drug-food, and drug-herbal interactions. Attendees at the JADPRO Live Virtual 2021 conference learned about the pharmacodynamic and pharmaco...

Cardio-Oncology Considerations in Oncologic Treatment Decisions

Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN

At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy....

Mental Health in the Oncology Setting: General Considerations and Treatment Tips

Lisa W. Goldstone, MS, PharmD, BCPS, BCPP

Patients with comorbid mental health and substance use disorders are at greater risk for mortality and have higher cancer care costs. At JADPRO Live Virtual 2021, Lisa W. Goldstone, MS, PharmD, BCPS, BCPP, talked through general consider...

An AP Perspective on Infusion Reactions in the Era of Immunotherapy

Carrie Peterson, DNP, RN, AGNP-c

As cancer care advances, creative uses for immunotherapy continue to be developed, but it is also important to be cognizant of the risk for infusion reactions. At JADPRO Live Virtual 2021, Carrie Peterson, DNP, RN, AGNP-c, reviewed the d...

Direct Oral Anticoagulants and Cancer Thrombosis: What APs Need to Know

Mailey L. Wilks, DNP, APRN, NP-C

Patients with cancer are at high risk for developing cancer-associated blood clots. Mailey L. Wilks, DNP, APRN, NP-C, led a session at JADPRO Live Virtual 2021 on the risk of venous thromboembolism in patients with cancer, available anti...

Survivorship Care Challenges: Navigating Changing Concerns

Carrie Tompkins Stricker, PhD, RN, ANP-BC

Advanced practitioners are often in charge of planning and implementing care for cancer survivors, as noted by Carrie Tompkins Stricker, PhD, RN, ANP-BC, during JADPRO Live Virtual 2021. During a session at the conference, Dr. Stricker r...

Herbal Medicine: Friend or Foe?

Roberta Bourgon, ND

Many cancer patients report the use of supplements and herbal medicines but may not always disclose their use to their health-care team. Along with potential interactions, these therapies may also affect outcomes of treatment. During JAD...

Oncology Urgent Care Clinics: Understanding Utilization and Best Practices

Cara Fleming, AGPCNP-BC, AOCNP®, and Deirdre Kelly, AGACNP-BC

An oncology urgent care clinic can improve patient satisfaction, reduce emergency room visits, and lower health-care costs for patients and facilities. At a session taking place at JADPRO Live Virtual 2021, presenters on the frontlines o...

The Critical Role of Nutrition and Exercise: Optimization in the Patient With Cancer

Paul Wischmeyer, MD, EDIC, FCCM, FASPEN

Undergoing surgery is one of the greatest physical and emotional challenges a patient can face, and doing so without preparation can lead to increased complications and mortality. At JADPRO Live Virtual 2021, Paul Wischmeyer, MD, EDIC, F...

2020–2021 Drug Updates in Solid Tumors

Christine Cambareri, PharmD, BCPS, BCOP, CSP

During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their advers...

2020–2021 Drug Updates in Hematologic Malignancies

Kirollos Hanna, PharmD, BCPS, BCOP

During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safe...

2020–2021 Drug Updates: Investigational Therapeutics in the Pipeline

Donald C. Moore, PharmD, BCPS, BCOP, DPLA

During JADPRO Live Virtual 2021, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mecha...

Biomarker Jeopardy

Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Haleigh Mistry,(3) MS, PA-C

In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determi...

Immunotherapy for the Treatment of Triple-Negative Breast Cancer

Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®

At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the curren...

Lung Cancer Biomarker Speak: Teach Me the Language

Beth Sandy,(1) MSN, CRNP, and Jennifer Morrissette,(2) PhD, FACMG

A vital role of the advanced practitioner is to analyze biomarker testing reports and explain to patients how the results may impact their treatment. At JADPRO Live Virtual 2021, presenters reviewed the importance of molecular testing in...

Multidisciplinary Management of Pancreatic Cancer

Pelin Cinar, MD, MS, and Patricia Zendejas, MSN, ANP-C, AOCNP®

At JADPRO Live Virtual 2021, presenters reviewed the epidemiology of pancreatic cancer, treatment options for patients with different stages of pancreatic cancer, and the most common symptoms and complications related to pancreatic cance...

Updates in the Management of Renal Cell Carcinoma

Kirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-C

At JADPRO Live Virtual 2021, advanced practitioner experts reviewed clinical updates in the treatment of renal cell carcinoma, key patient counseling and monitoring considerations, and best practices to manage adverse events associated w...

Updates in Cholangiocarcinoma

Kristen O’Hagan, MSN, RN, ANP-BC, AOCNP®

Cholangiocarcinoma is a spectrum of invasive adenocarcinomas that arise in the intrahepatic, perihilar, or distal biliary tree, and is classified by location. During JADPRO Live Virtual 2021, Kristen O’Hagan, MSN, RN, ANP-BC, AOCNP®, dis...

Molecular Testing in Hematologic Malignancies

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®

Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS,...

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma

Alli McClanahan, APRN, and Megan Spychalla, PA-C

Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at ...

Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With AML

Ashley Leak Bryant,(1) PhD, RN, OCN®, FAAN, and Kaitlyn Buhlinger,(2) PharmD, BCOP, CPP

Recent advances have resulted in an expansion of treatment options for AML, especially targeted therapies and low-intensity regimens. At JADPRO Live Virtual 2021, presenters reviewed novel and targeted oral chemotherapy for adults with A...

The 4 T’s of ITP: Tailoring Therapies to Treat Thrombocytopenia

David Hughes, PharmD, BCOP

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David ...

Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape

Ashley Ames, FNP-BC, and Diane Lee, AGPCNP-BC

During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of p...

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021

Alexis C. Geppner, MLS, CTTS, PA-C

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data from a session on hyper-CVAD and additional therapies for patients with acute lymphoblastic leukemia presented by Elias Jabbour,...

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021

Alexis C. Geppner, MLS, CTTS, PA-C

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, distills information reviewed in the session on IDH-mutated acute myeloid leukemia presented by Courtney D. DiNardo, MD, MSCE, also of MD Anderson ...

Targeting p53 in MDS: Highlights From SOHO 2021

Alexis C. Geppner, MLS, CTTS, PA-C

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, evaluates data from the session on p53 in myelodysplastic syndrome presented by David A. Sallman, MD, of H. Lee Moffitt Cancer Center and Research ...

Updates on Clinical Trials for Myelofibrosis: Highlights From SOHO 2021

Lisa Nodzon, PhD, APRN, AOCNP®

Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews new therapeutic approaches in myelofibrosis presented in a session led by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2021 SOHO ...

Therapeutic Updates for Richter Syndrome: Highlights From SOHO 2021

Lisa Nodzon PhD, APRN, AOCNP®

Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews an update on treating Richter Syndrome, which was discussed in a session presented by Davide Rossi, MD, PhD, of Institute of Southern Switzerland, at the 2021 SOHO Annual M...

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021

Lisa Nodzon PhD, APRN, AOCNP®

Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews data on clinical trials and future directions in BCMA-directed CAR T cells presented in a session by Jesus G. Berdeja, MD, of Sarah Cannon Cancer Institute, at the 2021 SOH...

Immunotherapy Approaches in T-Cell Lymphoma: Highlights From SOHO 2021

Kelly Valla, PharmD, BCOP

At the 2021 SOHO Annual Meeting, Maksim Mamonkin, PhD, of Baylor College of Medicine, reviewed progress in immunotherapy for T-cell lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses key insig...

The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021

Kelly Valla, PharmD, BCOP

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, describes the clinical implications of novel agents for aggressive B-cell lymphoma, which were described at a session presented by Gilles Salles, MD, PhD, of Mem...

Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021

Kelly Valla, PharmD, BCOP

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, evaluates novel treatment approaches in relapsed/refractory mantle cell lymphoma, as presented by Kami J. Maddocks, MD, of Ohio State University, at the 2021 SOH...

Abstracts From JADPRO Live 2021

VIRTUAL • OCTOBER 7–17The posters for the abstracts below can be found at JADPROLive.com

Breast Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Sheeba Cantanelli, MPAS, PA-C

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, discusses results from studies evaluating adjuvant therapy with a PARP inhibitor in BRCA-mutated HER2-negative metastatic breast cance...

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

Presented by Rasheda Persinger, AGNP-C

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, a...

A Multidisciplinary Approach to Head and Neck Cancer

Presented by Casey Fazer-Posorske, PA-C

At JADPRO Live Virtual 2020, Casey Fazer-Posorske, PA-C, provided updates in the management of patients with head and neck cancer, including the types of head and neck cancers, their associated treatments and side-effect management, the ...

Developments in Hepatocellular Cancer Treatment

Presented by Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®

The treatment landscape of hepatocellular cancer has changed significantly within the past few years. At JADPRO Live Virtual 2020, Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®, provided an overview of developments in hepatocellular cancer ...

Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct

Presented by Kristen O’Hagan, ANP-BC, MS, AOCNP®

During JADPRO Live Virtual 2020, Kristen O’Hagan, ANP-BC, MS, AOCNP®, provided an overview of rare gastrointestinal tumors, their presentation, and current treatment algorithms. Ms. O’Hagan also discussed the advanced practitioner’s role...

Kidney Cancer Combinations: Tracking and Treating Symptoms With the Challenge of Combination Therapy

Presented by Kathleen Burns, AGACNP-BC, OCN®

At JADPRO Live Virtual 2020, Kathleen Burns, AGACNP-BC, OCN®, discussed strategies to track and treat symptoms associated with combination therapies for the treatment of renal cell carcinoma. 

Sarcoma: Disease Overview and Treatment Updates

Presented by Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS

During JADPRO Live Virtual 2020, Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS, highlighted the clinical features and diagnostic workup of soft-tissue sarcoma and presented on a multidisciplinary approach to treatment planni...

Optimizing Treatment of Chronic Lymphocytic Leukemia

Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®

During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, described personalization of the treatment of chronic lymphocytic leukemia (CLL) using molecular attributes of the disease, as well as patient characteristics. Dr. Kurtin...

Diagnosis and Treatment of AL and ATTR Amyloidosis

Presented by Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®

At JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®, differentiated between AL and ATTR amyloidosis, discussed key considerations in selecting therapy, and identified wa...

Improving Outcomes in Hematopoietic Stem Cell Transplant: Recent Advances

Presented by Maritza Alencar, DNP, MBA, APRN-BC, BMTCN

During JADPRO Live Virtual 2020, Maritza Alencar, DNP, MBA, APRN-BC, BMTCN, described advances in the management and prevention of infectious disease complications and graft-vs.-host disease following transplant. Dr. Alencar also emphasi...

Hemolytic Anemias: Autoimmune and Beyond

Presented by Ravi Krishnadasan, MD, FACP

During JADPRO Live Virtual 2020, Ravi Krishnadasan, MD, FACP, provided an overview of the terminology of hemolysis, laboratory tests used in the diagnosis of hemolytic anemias, and appropriate indications for treatment of the various hem...

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

Presented by Val R. Adams, PharmD, FCCP, FHOPA, BCOP

During the JADPRO Live Virtual 2020 conference, Val R. Adams, PharmD, FCCP, FHOPA, BCOP, discussed how to determine which patients with cancer should be treated with direct oral anticoagulants (DOACs), the similarities and differences be...

Approach to the Hospitalized Patient With Thrombocytopenia

Presented by Laura J. Zitella, MS, RN, ACNP-BC, AOCN®

During the 2020 JADPRO Live Virtual conference, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, educated the audience on the most important causes of thrombocytopenia in hospitalized patients and diagnostic approaches to employ. 

Mitigating the Morbidity of Financial Toxicity in Cancer Care

Presented by Veena Shankaran, MD, MS

At JADPRO Live Virtual 2020, Veena Shankaran, MD, MS, reviewed data around the prevalence and risk factors for financial toxicity, discussed potential downstream consequences of financial toxicity in cancer care, and outlined four key st...

2019–2020 Drug Updates in Solid Tumors

Presented by Kirollos S. Hanna, PharmD, BCPS, BCOP

During JADPRO Live Virtual 2020, Kirollos S. Hanna, PharmD, BCPS, BCOP, updated the audience on the pharmacology, new indications, and the clinical trial data of novel medications as well as expanded indications in solid tumors. Dr. Hann...

2019–2020 Drug Updates in Hematologic Malignancies

Presented by Heidi D. Finnes, PharmD, BCOP, FHOPA

During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed ...

Biomarker Jeopardy

Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Allyson Price,(3) MPAS, PA-C

The popular Biomarker Jeopardy session returned this year at JADPRO Live 2020. Sandra E. Kurtin, PhD, ANP-C, AOCN®, led the session, and was joined by Alyssa Henglefelt, PharmD, BCOP, and Allyson Price, PA-C. Using a Jeopardy format, the...

Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events

Presented by Lisa Kottschade, APRN, MSN, CNP

At JADPRO Live Virtual 2020, Lisa Kottschade, APRN, MSN, CNP, highlighted considerations for advanced practitioners on the recognition and monitoring of rare and life-threatening immune-related adverse events (irAEs), as well as strategi...

FDA and Its Role in Drug Development

Presented by Richard Pazdur, MD

JADPRO Live 2020 was honored to have Dr. Richard Pazdur, the Director of the Oncology Center of Excellence at the FDA, discuss recent changes to oncology drug development and the approval process, the roles of the advanced practitioner i...

Advanced Prostate Cancer: Considerations for Advanced Practitioners

Presented by Brenda Martone, MSN, ANP-BC, AOCNP®

At JADPRO Live Virtual 2020, Brenda Martone, MSN, ANP-BC, AOCNP®, discussed treatment options available for advanced prostate cancer patients and the role of genetics and genomics in patients with advanced prostate cancer. 

Advanced Practitioner Leadership in Times of Crisis

Presented by Gabrielle Zecha,(1) PA-C, MHA, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, David Johnson,(3) PA-C, and Sara Toth,(4) RN, APRN, FNP-C, AOCNP®, AGN-BC

JADPRO Live Virtual kicked off with the opening panel on advanced practitioner leadership during the COVID-19 pandemic. The group discussed their institutional emergency protocols, how they leveraged advanced practitioners (APs) to provi...

Words Matter: Use of Respectful Language in Oncology

Presented by Laura J. Zitella,(1) MS, RN, ACNP-BC, AOCN®, and Tatiana M. Prowell,(2) MD

During JADPRO Live Virtual 2020, Conference Chair Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, spoke with Tatiana M. Prowell, MD, about overcoming implicit bias, the power of language, and creating a culture of respect in oncology for both ...

Are Current Metrics Adequate to Demonstrate the Value of Oncology Advanced Practitioners?

Presented by Jason Astrin, DMSc, MBA, PA-C, DFAAPA

At JADPRO Live Virtual 2020, Jason Astrin, DMSc, MBA, PA-C, DFAAPA, defined the concepts of productivity and value and discussed strategies for measuring the value of oncology advanced practitioners in order to recognize advanced practit...

The Elevator Pitch: Communicating Your Expertise, Experience, and Value to Patients, Co-Workers, and Prospective Employers in an Instant

Presented by Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC

During JADPRO Live Virtual 2020, Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, provided guidance to advanced practitioners on creating their elevator pitch and communicating their role. 

Cardio-Oncology: The Intersection Between Cardiovascular Disease and Cancer

Presented by Jessica Shank Coviello, DNP, APRN, ANP-BC, and Kejal Amin, PharmD, MBA, BCOP

Cardio-oncology is a rapidly emerging field, and advanced practitioners (APs) play key roles in the prevention, early detection, and optimal treatment of cardiotoxicities associated with cancer therapies. At JADPRO Live Virtual 2020, Jes...

Management of Diabetes in the Patient With Cancer

Presented by Lorena A. Wright, MD, FACE

During JADPRO Live Virtual 2020, Lorena A. Wright, MD, FACE, reviewed the principles of antihyperglycemic management and discussed the importance of working as a team to collaborate in the management of patients with cancer.

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

Lisa Nodzon, PhD, ARNP, AOCNP®

 At the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, described the clinical implications of measuring minimal residual disease. Lisa Nodzon, Ph...

Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020

Kelly Valla, PharmD, BCOP

 At the 2020 SOHO Annual Meeting, Alex F. Herrera, MD, of City of Hope, discussed the integration of novel agents into the management of patients with relapsed or refractory Hodgkin lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer ...

Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020

Kelly Valla, PharmD, BCOP

 Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses takeaways from the session on relapsed T-cell lymphoma led by Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, at the 2020 SOHO Annua...

New CAR Designs: Highlights From SOHO 2020

Kelly Valla, PharmD, BCOP

 Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, considers exciting research on novel chimeric antigen receptor designs presented by Renier J. Brentjens, MD, PhD, of Memorial Sloan Kettering Cancer Center, at ...

Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020

Allyson Price, MPAS, PA-C

 Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, summarizes the session on the genomics of drug response in acute lymphoblastic leukemia presented by Jun J. Yang, PhD, of St. Jude’s Research Hospital, at ...

Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020

Allyson Price, MPAS, PA-C

 In his keynote presentation, John DiPersio, MD, PhD, of Washington University, recipient of the SOHO 2020 Distinguished Lecturer Award, discussed immunotherapy for T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma. All...

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020

Allyson Price, MPAS, PA-C

 Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, highlights implications for advanced practitioners from the presentation at the 2020 SOHO Annual Meeting by Guillermo Garcia-Manero, MD, also from MD Ander...

Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020

Lisa Nodzon, PhD, ARNP, AOCNP®

 Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO...

Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020

Lisa Nodzon, PhD, APRN, AOCNP®

 Lisa Nodzon, PhD, APRN, AOCNP®, of Moffitt Cancer Center, discusses key points on the management of early relapse in multiple myeloma, a session presented at the 2020 SOHO Annual Meeting by Robert Z. Orlowski, MD, PhD, of The University...

Gastrointestinal Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN®

Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was le...

Prostate Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, breaks down abstract summaries published in The ASCO Post on a novel target, imaging agent, and androgen-deprivation therapy for prostate cancer, along with their implicat...

Genitourinary (Non-Prostate) Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Jeannette Hammond, PA-C

Following coverage from The ASCO Post, Jeannette Hammond, PA-C, of Seattle Cancer Care Alliance, comments on the results of practice-changing studies on novel therapies in urothelial cancer and renal cell carcinoma.

Gynecologic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Following coverage by The ASCO Post, Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island, interprets findings from major gynecologic oncology abstracts featured in The ASCO Post and considers takeaways for adva...

Breast Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Paula Anastasia,(1) RN, MN, AOCN®, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®

Paula Anastasia, RN, MN, AOCN®, of UCLA Health Medical Center, and Wendy H. Vogel, MSN, FNP, AOCNP®, of Harborside, discuss results from studies evaluating therapies in women with de novo metastatic breast cancer and HER2-positive breast...

Thoracic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews the major abstracts in thoracic cancers from the ASCO20 Virtual Scientific Program using coverage by The ASCO Post and offers considerations for advanced ...

Melanoma: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Lisa Kottschade, APRN, MSN, CNP

With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews clinical data on which patients with metastatic melanoma should receive combination therapy vs. single-agent PD-1 up front, and what to do at the ti...

Other Solid Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Elizabeth S. Waxman,(1) RN, MSN, AOCN®, ANP-BC, and Abby Fuoto,(2) DNP, ANP-BC, AOCNP®, ACHPN

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, evaluates a study showing activity by pralsetinib in patients with a variety of tumors harboring RET gene fusions, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of ...

Hematologic Malignancies: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Amy Pierre,(1) MSN, ANP-BC, P. Andrew Allred,(2) MS, PA-C, and Allyson Price,(3) PA-C

Amy Pierre, MSN, ANP-BC, of Memorial Sloan Kettering Cancer Center, P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, and Allyson Price, PA-C, of MD Anderson Cancer Center, provide expert insights for advanced practitioner...

Issues in Oncology: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Josh Epworth, ARNP

Josh Epworth, ARNP, of Seattle Cancer Care Alliance/University of Washington Medical Center, distills three influential abstracts from the ASCO virtual meeting and reflects on how advanced practitioners can use the findings to improve th...

Precision Oncology Comes of Age: Tumor-Agnostic Approaches

Presented by Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite ...

Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment

Presented by Krista M. Rubin,(1) MS, FNP-BC, and Anthony J. Olszanski,(2) MD, RPh

At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based comb...

First-Line Therapy for Metastatic Non–Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches

Presented by Joshua Bauml, MD, and Christina Knepley, CRNP

At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding c...

Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments

Presented by Heather R. Greene, MSN, FNP, AOCNP®, and Lee S. Schwartzberg, MD, FACP

Heather R. Greene, MSN, FNP, AOCNP®, and Lee S. Schwartzberg, MD, FACP, discussed the current and future treatment landscape for triple-negative breast cancer, including recent and emerging data on approved treatments, novel therapeutic ...

Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices

Presented by Jame Abraham, MD, and Kelley D. Mayden, MSN, FNP, AOCNP®

Through expert, case-based discussion, Jame Abraham, MD, and Kelley Mayden, MSN, FNP, AOCNP®, presented existing and emerging data for current and investigational therapies for HER2-positive breast cancer and their associated adverse eve...

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices

Presented by Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®

Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment. 

Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes

Presented by Amanda M. Viereck, PA-C, and Anthony J. Olszanski, MD, RPh

Checkpoint inhibitors and oncolytic vaccine therapy have transformed the management of metastatic melanoma. This article presents the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the ...

Improving Outcomes for Patients With Advanced Urothelial Carcinoma

Presented by Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C

At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selectio...

Current and Future Directions for PARP Inhibition

Presented by Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD

Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that incl...

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma

Presented by Edward Libby,(1) MD, and Josh Epworth,(2) ARNP

Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minim...

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma

Presented by Amy E. Pierre,(1) MSN, ANP-BC, and Joshua Richter,(2) MD

Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events,...

Biomarker BINGO

Presented by Lauren Held, PharmD, BCOP,(1) Sandra Kurtin,(2) PhD, ANP-C, AOCN®, and Lee Schwartzberg,(3) MD, FACP

This JADPRO Live session tested attendees’ knowledge on biomarkers and their use in determining targeted therapy for certain tumor types, key assays used to measure common biomarkers, and guideline-endorsed biomarker testing recommendati...

Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances

Presented by Patricia Mangan, RN, MSN, CRNP, and Edward Stadtmauer, MD

At JADPRO Live 2019, Patricia Mangan, RN, MSN, CRNP, and Edward Stadtmauer, MD, discussed the emerging world of chimeric antigen receptor (CAR) T-cell therapy, including the CAR T-cell process, approved indications and studies in hematol...

Challenges of Integrating Biosimilars Into Clinical Practice

Presented by Kate Jeffers,(1) PharmD, MHA, BCOP, Megan May,(2) PharmD, BCOP, and Wendy H. Vogel,(3) MSN, FNP, AOCNP®

Presenters at JADPRO Live 2019 discussed the chemical and clinical nature of biosimilars, reviewed biosimilar development in oncology, and discussed implementation strategies for biosimilars. 

2018–2019 Drug Updates in Hematologic Malignancies

Presented by Lauren Held, PharmD, BCOP

Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe...

2018–2019 Drug Updates in Solid Tumors

Presented by Sally Barbour, PharmD, BCOP, CPP, FHOPA

Sally Barbour, PharmD, BCOP, CPP, FHOPA, updated attendees on the FDA-approved therapies for initial or expanded indications for solid tumors across the past year, as well as their supporting clinical trial data and best practices for sa...

Improving Outcomes for Patients With Metastatic Colorectal Cancer: Challenges and Strategies

Presented by Leslie A. Swanson,(1) ARNP, and Kathleen Boyle,(2) PA-C

At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for exist...

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia

Presented by Mazyar Shadman,(1,2) MD, MPH, and Amy Goodrich,(3) CRNP

Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adver...

Addressing the Challenges of Aggressive Lymphomas

Presented by Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP

Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP, covered how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recom...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer

Jennifer L. Glass, PA-C, MS

Following coverage by The ASCO Post, Jennifer L. Glass, PA-C, MS, of the Mayo Clinic dives into the major findings in prostate cancer from the 2019 ASCO Annual Meeting in Chicago and their implications for advanced practitioners.

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Non–Small Cell Lung Cancer

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Cent...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Melanoma

Lisa Kottschade, APRN, MSN, CNP

In recent years, there has been an explosion of therapies for the treatment of melanoma, including BRAF mutation–guided therapy. With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of the Mayo Clinic reviews clinical data su...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Other Solid Cancers

Amy Hacker-Prietz, (1) MS, PA-C, Abby Fuoto, (2) DNP, ANP-BC, AOCNP®, ACHPN, Nanette Fong, (3) RN, MSN, and P. Andrew Allred, (4) MS, PA-C

Trials studying additional solid cancers, such as pancreatic cancer, head and neck cancer, glioblastoma, and glioma are reviewed in this section and accompanied by advanced practitioner commentaries. In addition, a study exploring the be...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Issues in Oncology

Pamela Hallquist Viale, RN, MS, CNS, ANP

Several abstracts presented at the ASCO Annual Meeting reflected the meeting theme of providing high-quality care to every patient. Following coverage by The ASCO Post, Editor-in-Chief to JADPRO, Pamela Hallquist Viale, RN, MS, CNS, ANP,...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gastrointestinal Cancer

Carolyn Grande, CRNP, AOCNP®

Using coverage from The ASCO Post of the ASCO Annual Meeting, Carolyn Grande, CRNP, AOCNP®, of the University of Pennsylvania Health System evaluates study findings in gastrointestinal cancer and discusses what advanced practitioners sho...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Genitourinary (Non-Prostate) Cancers

Jeannette Hammond, PA-C

Jeannette Hammond, PA-C, of the Seattle Cancer Care Alliance comments on major research presented at the ASCO Annual Meeting: a study addressing an unmet need in the metastatic urothelial cancer setting, a study showing no benefit from a...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gynecologic Cancers

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of the Women & Infants Hospital of Rhode Island offers commentary on major gynecologic cancer abstracts featured from the ASCO Annual Meeting by The ASCO Post, including findings in carcinosarcoma of th...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies

Amy Pierre, MSN, ANP-BC, and Nancy M. Nix, PharmD, BCPS, BCOP

Amy Pierre, MSN, ANP-BC, of the Memorial Sloan Kettering Cancer Center, and Nancy M. Nix, PharmD, BCPS, BCOP of St. Joseph’s/Candler Health System offer an advanced practitioner perspective on trials assessing the efficacy and safety of ...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Breast Cancer

Wendy H. Vogel, MSN, FNP, AOCNP®

Wendy H. Vogel, MSN, FNP, AOCNP®, of Wellmont Cancer Institute discusses results from a study in hormone receptor–positive metastatic breast cancer (MONALEESA-7), two studies in the metastatic HER2-positive setting (SOPHIA and NALA), as ...

2017-2018 Drug Approvals in Solid Tumors

Presented by Patrick J. Kiel, PharmD, BCPS, BCOP

New oncology approvals from 2017 to 2018 were mostly for additional indications, with many agents moved up to first-line therapy. Patrick J. Kiel, PharmD, BCPS, BCOP, detailed their implications for advanced practice.

2017-2018 Drug Updates in Hematologic Malignancies

Presented by Rebecca J. Nelson, PharmD, BCOP

Presented by Rebecca J. Nelson, PharmD, BCOP, Dr. Nelson discussed the pharmacology and indications of medications approved from 2017 to 2018 for the management of patients with hematologic malignancies.

Treating Venous Thrombosis in Oncology

Presented by Rowena Schwartz, PharmD, BCOP

According to Rowena Schwartz, PharmD, BCOP, it is important to consider broad treatment options, both direct oral anticoagulants and older agents such as heparin, when treating patients with venous thromboembolism, as the newer agents ma...

Advances in the Treatment of HER2-Positive Breast Cancer

Presented by Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C

Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C, reviewed landmark clinical trials of adjuvant therapies for women with HER2–positive breast cancer and emphasized the key role of advanced practitioners in managing adverse eve...

Surgical Implications for Women With Breast Cancer

Presented by Sherry Goldman, MSN, NP, CBCN

At JADPRO Live 2018, Sherry Goldman, MSN, NP, CBCN, delved into different surgical rationales for lumpectomy, mastectomy, and mastectomy with reconstructions. Ms. Goldman also explored the benefits and disadvantages associated with nippl...

Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology

Presented by Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP

Advanced practitioners play an important role in recognizing and treating adverse events caused by multimodality therapies in lung cancer. Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP, detailed strategies f...

Evolving Therapies in the Clinical Management of Melanoma

Presented by Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD

Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD, shared clinical data supporting the use of emerging targeted therapies and immunotherapies in the treatment of metastatic melanoma.

Multimodal Therapies for Head and Neck Cancer

Presented by Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN

HPV-related head and neck cancer is emerging as an epidemic in the US population. At JADPRO Live, Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, evaluated risk factors and prevention strategies. They also discussed...

Sequencing of Treatments for Patients With Ovarian Cancer

Presented by Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD

Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD, discussed the indications for the three PARP agents (olaparib, rucaparib, and niraparib) and strategies for managing PARP inhibitor–related side effects.

Sequencing Therapies in Renal Cell Carcinoma

Presented by Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®

Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®, explained the use of tyrosine kinase inhibitors in the adjuvant setting in patients with advanced renal cell carcinoma, as well has how to best utilize immunotherapy in this set...

Sequencing Therapies in Indolent Lymphomas

Presented by Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®

Several targeted agents have recently emerged for the treatment chronic lymphocytic leukemia and follicular lymphoma, which has made treatment selection more complex. Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®, descri...

Modern Management of Classical Hodgkin Lymphoma

Presented by Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD

Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and lo...

Advances in the Management of Myeloma

Presented by Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD

New agents for the treatment of myeloma have individual and class effects that advanced practitioners need to know about when helping to keep their patients on treatment regimens. At JADPRO Live, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, an...

CAR T-Cell Therapy and the Pharmacology of Managing Cytokine Release Syndrome

Presented by Jae Park, MD, and Amber C. King, PharmD, BCOP

Jae Park, MD, and Amber C. King, PharmD, BCOP, shared background and clinical information regarding CAR T-cell therapy in acute lymphoblastic leukemia and large-cell lymphoma, as well as strategies to mitigate cytokine release syndrome a...

Differential Diagnosis and Testing for Hematologic Malignancies

Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD

Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD, provided advice to the advanced practitioner audience on appropriately applying diagnostic tests in order to acquire actionable information about a patient’s disease.

New Directions in Acute Myeloid Leukemia

Presented by Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP

Acute myeloid leukemia (AML) is diagnosed in about 20,000 people a year and remains a very challenging malignancy to treat. Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP, reviewed the basics of treating AML, including new asse...

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on...

New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents

FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these d...

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Immunotherapy has proven activity in several types of cancer; however, the mechanisms of action of immunotherapy can cause several different immune-related toxicities. Advanced practitioners are in a unique position to recognize the timi...

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer

Neratinib following the completion of trastuzumab has been shown to reduce the risk of disease recurrence for patients with HER2-positive early breast cancer in whom extended adjuvant therapy seems advisable. In clinical trials, the most...

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ...

Hereditary Aspects of Colorectal Cancer: Mismatch Repair Genes Drive Lynch Syndrome

Lynch syndrome is the most common inherited form of colorectal cancer, affecting approximately 1 in 279 individuals, or 1.2 million people in the United States. It's also associated with a predisposition to endometrial, ovarian, and stom...

Advances in the Management of Patients With Urothelial Carcinomas of the Bladder

For more than 30 years, there were no new treatments in bladder cancer. Then, in 2016, there were five drug approvals. JADPRO Live presenters delved into recent advancements and opportunities for improving outcomes for patients with blad...

Optimizing Outcomes for Patients With Soft-Tissue Sarcoma Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

A multidisciplinary team can help improve the outcomes of patients with any cancer, but particularly so for patients with soft-tissue sarcomas, as discussed at JADPRO Live. During this presentation, MD, PA, and NP colleagues from Moffitt...

Multiple Myeloma: Risk Stratification and Toxicity Management

The treatment landscape for multiple myeloma is rapidly changing. At JADPRO Live 2017, presenters brought advanced practitioners up to date on the newest approaches to the management of this disease, as well as what to be aware of when t...

A Deeper Dive Into Advanced and Future Directions in Treating Patients With Acute Myeloid Leukemia

Acute myeloid leukemia is a disease that affects predominantly older patients, with a median age at diagnosis of 68. Overall prognosis is poor, but novel therapies that have emerged in recent years offer hope that outcomes can improve. I...

Contemporary Management of Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Identifying key molecular attributes can help in the risk-adapted treatment of Hodgkin lymphoma and chronic lymphocytic leukemia. At JADPRO Live, presenters reviewed best practices for managing patients with the rapidly expanding armamen...

Advances in the Use of Immunotherapy in Oncology

Innovations in cancer immunotherapy have created new options for patients and avenues for clinicians to practice precision medicine.

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies

There have been promising results from clinical trials on the efficacy of engineering patients' immune cells to treat their cancers. CAR T-cell therapy also has unique toxicities advanced practitioners should be aware of.

Optimal Collaborative Management of Patients With Esophagogastric Cancers

The addition of radiation to preoperative chemotherapy and newer therapeutic combinations add to treatment options for these difficult-to-treat cancers.

Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma

Novel therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique immune-related advers...

Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer

Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and ma...

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

Multidisciplinary clinics for pancreatic cancer such as one established at Johns Hopkins offer advantages in the care of patients with pancreatic cancer. Advanced practitioners can play a role in multidisciplinary care, providing symptom...

Advances in Collaborative Practice for Patients With Head and Neck Cancers

Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newe...

Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung

Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.

New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia

Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, there is a need for advanced practitioners to stay up to date and info...

Nuances in the Management of Aggressive Lymphomas

Treatment for both Hodgkin and Non-Hodgkin lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, adv...

New Treatment Strategies Making an Impact in Multiple Myeloma

Even though multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions and the management of toxicities related to newer dru...

Best Practices in the Management of Infectious Complications for Patients With Cancer

As antibiotic resistant bacteria are becoming ubiquitous, managing infection becomes more complex. Optimizing preventive measures, early diagnosis, and management of infection is of the highest priority in cancer care.

Management of Venous Thromboembolism for Patients With Hematologic Malignancies

Advanced practitioners are an integral part of the cancer care team. Therefore, it is imperative they are knowledgeable of risk factors associated with venous thromboembolism in the oncology setting, including signs or symptoms and manag...

Management of Patients With Chemotherapy-Induced Nausea and Vomiting

Despite advances in the management of chemotherapy-induced nausea and vomiting (CINV), clinical management remains a challenge and CINV continues to be a side effect that patients fear most. Advanced practitioners can play a major role i...

Biosimilars: Beginning a Conversation

Revolution at the Corner Drugstore

Getting Familiar With Biosimilars

2015 Review of Newly Approved Oncologic Therapies

Ovarian Cancer: Current Treatment and Patient Management

Collaborative Practice in the Management of Neuroendocrine Tumors

Patients Living Longer With Metastatic Colorectal Cancer

Evolving Paradigms in Melanoma Therapy

New Agents for the Management of Advanced HER2-Positive Breast Cancer

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non–Small Cell Lung Cancer

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer

What Radiation Oncology Wants Medical Oncology to Know

Diagnostic Radiology: What the Advanced Practitioner Needs to Know

Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

Risk Stratification in Multiple Myeloma: Putting the Pieces Together

Outpatient Management of the Hematopoietic Stem Cell Transplant Patient

Diagnosis and Treatment of Benign Bleeding Disorders

Management of Dermatologic Toxicities Associated With Targeted Therapy

Management of Weight Loss in People With Cancer

The Role of Exercise and Rehabilitation in the Cancer Care Plan

Incorporating a Survivorship Clinic Into Practice

The Launch of the Advanced Practitioner Society for Hematology and Oncology (APSHO)

Advanced Practitioners in Oncology: Diverse Experiences, Shared Challenges

Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners

2011 National Comprehensive Cancer Network (NCCN) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™

These three reports (on pages 211–216) are from the 2011 National Comprehensive Cancer Network® (NCCN®) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™, a meeting held on March 9–13, 2011, in Hollywood, Flori...

Reports from the 2010 ASCO Annual Meeting

2010 National Comprehensive Cancer Network (NCCN) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™

These four reports (from page 55–62) are from the 2010 National Comprehensive Cancer Network (NCCN) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™, a meeting held on March 10, 2010, in Hollywood, Florida. Re...

Meet The Panel